Literature DB >> 25898924

Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism.

Camila Oliveira Freitas Machado1, Karina Griesi-Oliveira1,2, Carla Rosenberg2, Fernando Kok2,3, Stephanie Martins1, Maria Rita Passos-Bueno2, Andrea Laurato Sertie1.   

Abstract

Protein synthesis regulation via mammalian target of rapamycin complex 1 (mTORC1) signaling pathway has key roles in neural development and function, and its dysregulation is involved in neurodevelopmental disorders associated with autism and intellectual disability. mTOR regulates assembly of the translation initiation machinery by interacting with the eukaryotic initiation factor eIF3 complex and by controlling phosphorylation of key translational regulators. Collybistin (CB), a neuron-specific Rho-GEF responsible for X-linked intellectual disability with epilepsy, also interacts with eIF3, and its binding partner gephyrin associates with mTOR. Therefore, we hypothesized that CB also binds mTOR and affects mTORC1 signaling activity in neuronal cells. Here, by using induced pluripotent stem cell-derived neural progenitor cells from a male patient with a deletion of entire CB gene and from control individuals, as well as a heterologous expression system, we describe that CB physically interacts with mTOR and inhibits mTORC1 signaling pathway and protein synthesis. These findings suggest that disinhibited mTORC1 signaling may also contribute to the pathological process in patients with loss-of-function variants in CB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25898924      PMCID: PMC4795228          DOI: 10.1038/ejhg.2015.69

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  33 in total

1.  Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.

Authors:  Guomei Tang; Kathryn Gudsnuk; Sheng-Han Kuo; Marisa L Cotrina; Gorazd Rosoklija; Alexander Sosunov; Mark S Sonders; Ellen Kanter; Candace Castagna; Ai Yamamoto; Zhenyu Yue; Ottavio Arancio; Bradley S Peterson; Frances Champagne; Andrew J Dwork; James Goldman; David Sulzer
Journal:  Neuron       Date:  2014-08-21       Impact factor: 17.173

2.  Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina.

Authors:  Mrinalini Hoon; Tolga Soykan; Björn Falkenburger; Matthieu Hammer; Annarita Patrizi; Karl-Friedrich Schmidt; Marco Sassoè-Pognetto; Siegrid Löwel; Tobias Moser; Holger Taschenberger; Nils Brose; Frédérique Varoqueaux
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

3.  Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.

Authors:  C A Hoeffer; E Sanchez; R J Hagerman; Y Mu; D V Nguyen; H Wong; A M Whelan; R S Zukin; E Klann; F Tassone
Journal:  Genes Brain Behav       Date:  2012-02-15       Impact factor: 3.449

4.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

5.  Collybistin, a newly identified brain-specific GEF, induces submembrane clustering of gephyrin.

Authors:  S Kins; H Betz; J Kirsch
Journal:  Nat Neurosci       Date:  2000-01       Impact factor: 24.884

6.  The autistic neuron: troubled translation?

Authors:  Raymond J Kelleher; Mark F Bear
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

7.  Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin.

Authors:  Alexandros Poulopoulos; Gayane Aramuni; Guido Meyer; Tolga Soykan; Mrinalini Hoon; Theofilos Papadopoulos; Mingyue Zhang; Ingo Paarmann; Céline Fuchs; Kirsten Harvey; Peter Jedlicka; Stephan W Schwarzacher; Heinrich Betz; Robert J Harvey; Nils Brose; Weiqi Zhang; Frédérique Varoqueaux
Journal:  Neuron       Date:  2009-09-10       Impact factor: 17.173

8.  A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation.

Authors:  Vera M Kalscheuer; Luciana Musante; Cheng Fang; Kirsten Hoffmann; Celine Fuchs; Eloisa Carta; Emma Deas; Kanamarlapudi Venkateswarlu; Corinna Menzel; Reinhard Ullmann; Niels Tommerup; Leda Dalprà; Andreas Tzschach; Angelo Selicorni; Bernhard Lüscher; Hans-Hilger Ropers; Kirsten Harvey; Robert J Harvey
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

Review 9.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders.

Authors:  Mauro Costa-Mattioli; Lisa M Monteggia
Journal:  Nat Neurosci       Date:  2013-10-28       Impact factor: 24.884

10.  The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering.

Authors:  Kirsten Harvey; Ian C Duguid; Melissa J Alldred; Sarah E Beatty; Hamish Ward; Nicholas H Keep; Sue E Lingenfelter; Brian R Pearce; Johan Lundgren; Michael J Owen; Trevor G Smart; Bernhard Lüscher; Mark I Rees; Robert J Harvey
Journal:  J Neurosci       Date:  2004-06-23       Impact factor: 6.167

View more
  18 in total

Review 1.  Gephyrin: a key regulatory protein of inhibitory synapses and beyond.

Authors:  Femke L Groeneweg; Christa Trattnig; Jochen Kuhse; Ralph A Nawrotzki; Joachim Kirsch
Journal:  Histochem Cell Biol       Date:  2018-09-27       Impact factor: 4.304

2.  The phenotypic spectrum of ARHGEF9 includes intellectual disability, focal epilepsy and febrile seizures.

Authors:  Karl Martin Klein; Manuela Pendziwiat; Anda Eilam; Ronit Gilad; Ilan Blatt; Felix Rosenow; Moien Kanaan; Ingo Helbig; Zaid Afawi
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

3.  ARHGEF9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation.

Authors:  Jing-Yang Wang; Peng Zhou; Jie Wang; Bin Tang; Tao Su; Xiao-Rong Liu; Bing-Mei Li; Heng Meng; Yi-Wu Shi; Yong-Hong Yi; Na He; Wei-Ping Liao
Journal:  Neurogenetics       Date:  2017-11-13       Impact factor: 2.660

Review 4.  eIF3: a factor for human health and disease.

Authors:  Andreia Gomes-Duarte; Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  RNA Biol       Date:  2017-11-13       Impact factor: 4.652

Review 5.  The role of GABAergic signalling in neurodevelopmental disorders.

Authors:  Xin Tang; Rudolf Jaenisch; Mriganka Sur
Journal:  Nat Rev Neurosci       Date:  2021-03-26       Impact factor: 34.870

6.  Receptor tyrosine kinase EphA7 is required for interneuron connectivity at specific subcellular compartments of granule cells.

Authors:  Simone Beuter; Ziv Ardi; Omer Horovitz; Jennifer Wuchter; Stefanie Keller; Rinki Saha; Kuldeep Tripathi; Rachel Anunu; Orli Kehat; Martin Kriebel; Gal Richter-Levin; Hansjürgen Volkmer
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

Review 7.  Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities.

Authors:  Valentina Zamboni; Rebecca Jones; Alessandro Umbach; Alessandra Ammoni; Maria Passafaro; Emilio Hirsch; Giorgio R Merlo
Journal:  Int J Mol Sci       Date:  2018-06-20       Impact factor: 5.923

8.  Eukaryotic initiation factor EIF-3.G augments mRNA translation efficiency to regulate neuronal activity.

Authors:  Stephen M Blazie; Seika Takayanagi-Kiya; Katherine A McCulloch; Yishi Jin
Journal:  Elife       Date:  2021-07-29       Impact factor: 8.713

9.  Missense Mutation R338W in ARHGEF9 in a Family with X-linked Intellectual Disability with Variable Macrocephaly and Macro-Orchidism.

Authors:  Philip Long; Melanie M May; Victoria M James; Simone Grannò; John P Johnson; Patrick Tarpey; Roger E Stevenson; Kirsten Harvey; Charles E Schwartz; Robert J Harvey
Journal:  Front Mol Neurosci       Date:  2016-01-20       Impact factor: 5.639

Review 10.  Rho GTPase Regulators and Effectors in Autism Spectrum Disorders: Animal Models and Insights for Therapeutics.

Authors:  Daji Guo; Xiaoman Yang; Lei Shi
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.